Secreted protein acidic and rich in cysteine (SPARC) is a non-structural extracellular matrix 35 protein that regulates interactions between the matrix and neighboring cells. In the 36 cardiovascular system, it is expressed by cardiac fibroblasts, endothelial cells, and in lower 37 levels by ventricular cardiomyocytes. SPARC expression levels are increased upon 38 myocardial injury and also during hypertrophy and fibrosis. We have previously shown 39 that SPARC improves cardiac function after myocardial infarction by regulating post-40 synthetic procollagen processing, however whether SPARC directly affects cardiomyocyte 41 contraction is still unknown. In this study we demonstrate a novel inotropic function for 42 extracellular SPARC in the healthy heart as well as in the diseased state after myocarditis-43 induced cardiac dysfunction. We demonstrate SPARC presence on the cardiomyocyte 44 membrane where it is co-localized with the integrin-beta1 and the integrin-linked kinase. 45
Introduction
1x10 10 adenoviral PFU containing GFP or SPARC was injected into the tail of 12 week old 118 C57Bl6 mice. 119
For viral myocarditis (VM) experiments, 3-5 week old male susceptible C3H mice (Harlan, 120 Boxmeer, The Netherlands) were inoculated intraperitoneally with 10 3 or 10 4 PFU CVB3 121 intraperitoneally. The heart was excised and cannulated via the aorta. Hearts were then 143 mounted onto a Langendorff perfusion setup and initially briefly rinsed with normal 144
Tyrode solution, containing (mM): 137 NaCl, 5.4 KCl, 0.5 MgCl2, 1 CaCl2, 11.8 Hepes, 10 145 2,3-Butanedione monoxime and 10 glucose, pH was adjusted to 7.4 with NaOH. 146
Subsequently it was perfused with a Ca 2+ -free solution for 8 min. The Ca 2+ -free Tyrode 147 solution contained (mM): 130 NaCl, 5.4 KCl, 1.2 KH2PO4, 1.2 MgSO4, 6 Hepes, 10 2,3-148
Butanedione monoxime, 20 glucose, and pH was adjusted to 7.2 with NaOH. Collagenase 149 II (672Units/ml, Worthington 4176) added to the Ca 2+free solution was subsequently 150 perfused for 8 min. The enzyme was then washed out for a further 3 mins with 0.09mM 151 CaCl2 and 50mg/ml BSA 0.18 mM CaCl2. The heart was then removed from the 152 Langendorff perfusion setup, and the myocytes were further dissociated mechanically by 153 gentle shaking. Ca 2+ was reintroduced stepwise. 154
Cell shortening was measured using video-edge detection (Ionoptix) during electrical field 155 stimulation at 1 and 2 Hz. Field stimulation was achieved with 5 ms square pulses of 156 constant voltage, at 20 % above threshold. The cell shortening is expressed as the 157 fractional shortening, i.e. normalized to resting cell length, ΔL/L0*100%. During field 158 stimulation cells were superfused with normal Tyrode solution at 37°C. [Ca2+]i was measured with fluo-3, and is reported as the fluorescence normalized to baseline values, 160 after background subtraction, F/F0. To measure the effect of SPARC ex vivo on cells, 161 recombinant SPARC (1μg/ml) was added to half of the freshly isolated cell suspension, 162 while the other half was left in normal Tyrode solution. Additionally, to assess the effects 163 of integrin-linked kinase (ILK) inhibition, CPD-22 (Calbiochem; 1µM) was utilized, whilst to 164 investigate the effect of myosin light chain kinase (MLCK) inhibition, ML-7 was used 165 (Sigma Aldrich; 3 µM). For all of the above interventions myocytes were incubated with 166 the specific agent(s) for 1 hour and then cell shortening was measured as described 167
above. 168
In vitro experiments with adult rat cardiac myocytes 169 Cardiac myocytes were isolated by enzymatic dissociation from adult Wistar rat hearts as 170 previously described [21] . Experiments were performed in accordance with the Guide for 171 the Animal Care and Use Committee of the VU University Medical Center (VUmc) and with 172 approval of the Animal Care Committee of the VUmc. For experiments, freshly isolated 173 cardiomyocytes were cultured at 37°C overnight on polyarcrylamide gels (25% 174 Acrylamide40%, 13% Bis2%) with a stiffness of approximately 15kPa. Prior to culture, 175 these gels were coated with laminin (10μg/ml), collagen (50μg/ml) with and without 176 recombinant SPARC (1μg/ml, PeproTech 120-36) in 0.1M HEPES, overnight at 4°C. The 177 cardiac myocytes were plated in plating medium (M199 medium, Gibco, 31150-022, with 178 1% Peniciline-Streptavidine and 5% fetal bovine serum) onto the coated gels, and after 1 179 hour incubation at 37°C, medium was replaced to culture medium (M199 medium with 1% Peniciline-Streptavidine, 0.2% Insulin Transferrin Sodium selenite and 0.1% 181 Cytochalasin D). After overnight incubation at 37°C, unloaded cell shortenings of the 182 adherent cardiac myocytes were measured in the culture medium, using different 183 frequencies of electrical field stimulation and analyzed using IonOptix software (IonOptix 184 LLC, Milton, MA). Data are presented as fractional shortening (% diastolic length), time to 185 peak of contraction (TTP) and 50% relaxation time (RT50). 186
Determining gel stiffness 187
Stiffness of fully hydrated gels was determined using a Piuma Nano-indentor (Optics 11, 188
Amsterdam, the Netherlands) in combination with an indentation probe with a stiffness 189 of 1 N/m and a tip radius of 44 um (Optics 11, Amsterdam, the Netherlands). The gel's 190
Young's modulus was determined by averaging 9 individual measurements. 191
Histology and microscopy 192
Cardiac tissue was processed and histochemical and immunohistochemical analyses were 193 performed as previously described [22] [23] [24] , and all morphometric analyses were done 194 on sections with myocyte in cross-sectional images. Hematoxylin and eosin -stained 195 sections (4 μm) were used to assess overall morphology. The number of CD-45 -staining 196 cells (monoclonal rat antibody, BD, 553076, clone 30-F11, 5μg/ml) was measured per 197 mm². Myocyte cross-sectional areas were calculated by measuring the inner 198 circumference of 150 myocytes per sample on laminin-stained sections (rabbit antibody, 199
Sigma, L9393, 125μg/ml). To assess the amount and cross-linking of fibrosis, Picro Sirius performed using a microscope (Leitz DMRXE; Leica), and QWin morphometry software 202 (Leica). All analyses were performed according to standard operating procedures. 203
Immunostaining of isolated cardiac myocytes 204
Adult cardiac myocytes were isolated from healthy mice as described, fixed in 2% PFA in 205 PBS for 10 min, incubated in 50mM glycine for 30 min to remove auto-fluorescence 206 caused by PFA at 488nm, and subsequently stained for SPARC (polyclonal goat antibody, 207 R&D systems, AF492, 5μg/ml) overnight at 4°C. The next day cells were initially incubated 208 with a secondary donkey-anti goat-alexa 488 labeled antibody for 90min. at room 209 temperature and some cells were subsequently stained for integrin beta1 (monoclonal 210 rat antibody, BD, 553715, 0.5μg/ml) for 4 hours at room temperature and afterwards 211 incubated with a secondary goat-anti rat-alexa 568 labeled antibody for 90min. at room 212 temperature. Cells were visualized with confocal microscopy on a Zeiss LSM700 213 microscope (Leica) using the Zen software (Leica), or analyzed using a BD FACSAria III flow 214 cytometer (Becton Dickinson (BD), San Jose, CA) and FlowJo software (Ashland, Oregon). 215
Immunostaining of the coated matrices 216
Matrices were produced and coated as described previously and stored at 4°C prior to 217 staining. Matrices were washed with PBS and subsequently stained for SPARC (polyclonal 218 goat antibody, R&D systems, AF491, 5μg/ml), laminin (polyclonal rabbit antibody, Sigma, 219 L9393, 5μg/ml) and collagen (monoclonal rat antibody, Merck Millipore, MAB 1912, 220 1/100) overnight at 4°C. The next day matrices were incubated with a secondary donkey-221 anti goat-alexa 660, goat-anti rabbit-alexa 568 and, goat-anti rat-alexa 488 labeled antibodies for 90min. at room temperature and matrices were visualized with confocal 223 microscopy on a Zeiss LSM700 microscope (Leica) using the Zen software (Leica). 224
Myocyte fractionation 225
Adult cardiac myocytes were isolated from healthy mice as described, incubated in lysis 226 buffer, containing (mM): 5 TrisHCl, 5 NaCl, 2 EDTA, 1 CaCl2, 1MgCl2, 2 DTT and pH was 227 adjusted to 7.4. Phosphatase inhibitors (2%, Sigma, P044 and P5726) and protease 228 inhibitors (4%, Roche, 11697498001) were added to the buffer, and cells were incubated 229 overnight at 4°C. The next day, the cell suspension was centrifuged for 1 hour at 4°C and 230 supernatant was collected as cytoplasmic fraction, the pellet was dissolved in lysis buffer 231 and collected as the membrane fraction. Student t-test for 2 groups or ANOVA, followed by a Bonferroni post hoc test for more 262 groups was used in most of the comparisons when groups passed the normality test.
When the standard deviation of two groups significantly differed, a Mann-Whitney test 264 for 2 groups or a Kruskal-Wallis test, followed by a Dunn's post hoc test for more groups, 265 was used. A paired Student's t test was used to analyze baseline and follow-up 266 echocardiographic measurements, a Wilcoxon test was used when data did not pass 267 normality test. A two-sided p-value of ≤ 0.05 was considered statistically significant. 
Extracellular SPARC increases cardiomyocyte contraction 272
To study how extracellular SPARC can improve cardiac function, we investigated whether 273 extracellular SPARC directly interacts with the cardiomyocytes. SPARC presence on the 274 cardiomyocyte increased when cells were isolated and incubated with 1mg/ml SPARC ex 275 vivo for 1h, as compared to cells incubated in normal buffer without SPARC ( Figure 1A) . 276
These SPARC-incubated cells demonstrated a higher cardiomyocyte cell shortening 277 ( Figure 1B and C), with no significant changes in contraction times (TTP) or relaxation 278 times (RT50) (Supplementary Figure 1A and B ). To mimic more in vivo conditions, we 279 coated matrices with physiological stiffness with laminin and collagen (Lam+Col) or 280 laminin, collagen and SPARC (Lam+Col+SPARC) ( Figure 1G ). SPARC, a known collagen-281 binding protein, co-localized with collagen on the matrices ( Figure 1D ) and importantly, 282 the presence of SPARC did not alter matrix stiffness ( Figure 1E ). Next, we isolated 283 cardiomyocytes from adult rats and cultured them overnight on these matrices. When stimulated at 0.5, 1 and 2 Hz, rat cardiomyocytes cultured on SPARC-containing matrices 285 demonstrated an increased cardiomyocyte shortening at all frequencies when compared 286 to cells cultured on matrices without SPARC ( Figure 1F ), while, once again, both TTP and 287 RT50 were unchanged (Supplementary Figure 1C and D). 288
289
Using Western Blot, we demonstrate SPARC presence in the membrane fraction, yet 290 absence in the cytosolic fraction of isolated cardiomyocytes ( Figure 1G ). Using 291 immunostaining and confocal microscopy we confirmed SPARC's presence on the 292 membrane of the cardiac myocyte, where it co-localizes with integrin-beta1 ( Figure 1H ). 293
Furthermore, immuno-precipitation demonstrated an interaction of SPARC with integrin-294 linked kinase (ILK) in both whole LV samples and in isolated cardiomyocytes ( Figure 1I ). 295
296
To investigate whether this SPARC-induced increased cardiomyocyte cell shortening is 297 through ILK-signaling, we incubated cells in the presence of SPARC and/or the ILK-298 inhibitor CPD-22. Importantly, the SPARC-induced increased cardiomyocyte cell 299 shortening is blunted in the presence of the ILK-inhibitor ( Figure 1J ). These results indicate 300 that SPARC increases cardiomyocyte cell shortening, at least in part, through ILK signaling. 301
Notably, CPD-22 alone did not affect cardiomyocyte shortening ( Figure 1J ). 302
303
In conclusion, these results demonstrate a direct binding of SPARC with the 304 cardiomyocyte membrane, where it appears to interact with ILK and is found in close 305 proximity to integrin-beta1. Moreover, SPARC presence on the membrane increases when cells are incubated in the presence of recombinant SPARC, resulting in increased 307 cardiomyocyte contraction, mediated -at least in part-through increased ILK signaling. an apparent onset of cardiac dilation suggested by an increased end systolic diameter 325 (ESD) ( Figure 2F ). Importantly, fractional shortening of isolated cardiomyocytes was also 326 compromised in this model ( Figure 2G ). Under field stimulation conditions, these cardiomyocytes did not display a prolonged TTP, but RT50 values were significantly 328 increased ( Supplementary Figure 2A and B) . 329 330 Next, using this low-dose VM model, we systemically injected SPARC with the adenoviral 331 vector with the intention of increasing cardiac SPARC expression ( Figure 2H ). One week 332 after CVB3 injection, Western Blotting revealed that cardiac SPARC levels were increased 333 in 3 out of the 4 mice from the adenoviral-SPARC injected group when compared to the 334 control adenoviral-GFP injected mice (Supplementary Figure 2C ). Five weeks after CVB3 335 injection, higher FS, and preserved ESD was measured in the SPARC overexpressing 336 animals as compared to GFP overexpression ( Figure 2I ,J), demonstrating that SPARC 337 overexpression prevents the development of cardiac dysfunction in this mild VM model. 338 Importantly, myocyte cross-sectional area, the amount of fibrosis, collagen cross-linking, 339 and the number of CD45 positive cells in the heart did not differ between the 2 groups, 5 340 weeks after CVB3 injection (Table 1) . Still, increased fractional shortening was 341 demonstrated by isolated cardiomyocytes from SPARC-overexpressing animals as 342 compared to isolated cardiomyocytes from control GFP overexpressing animals ( Figure  343 2K), indicating a protective, or positive inotropic effect of SPARC at the level of the 344 cardiomyocyte. Notably, no effect on contraction or relaxation times was observed 345 (Supplementary Figure 2E and F). Furthermore, despite SPARC being a Ca 2+ -binding 346 protein, we could not find indications that SPARC influenced Ca 2+ -handling, as there were 347 no differences in the Ca 2+ transient peak heights ( Figure 2L ), TTP or RT50 (Supplementary 348 Figure 3G and H) of these isolated myocytes. Moreover, we did not find any differences in Akt phosphorylation between LV samples from both groups, which is known to increase 350 intracellular Ca 2+ -availability and enhance contraction [26] , in LV samples from both 351 groups, as shown by Western Blotting (Figure 2M) We next wanted to assess the therapeutic potential for SPARC, using a high-dose CVB3 358 model with pronounced cardiac inflammation and fibrosis and severely compromised 359 cardiac function ( Figure 3A-F ). In this model, a higher dose of CVB3 (10 4 PFU CVB3) was 360 injected intraperitoneally in mice, resulting in severe cardiac inflammation after 1 week, 361
and prominent fibrosis and cardiomyocyte hypertrophy after 5 weeks ( Figure 3A -D) . 362
Here, cardiac function was even more compromised, as shown by severely decreased FS 363 ( Figure 3E) , and significantly increased ESD, indicating cardiac dilation in this model 364 ( Figure 3F ). To investigate the therapeutic potential of SPARC, we infused mice with 365 SPARC or vehicle for 72h implanting an osmotic minipump 5 weeks after initial viral 366 exposure, when dilated cardiomyopathy with severe inflammation and fibrosis had been 367 established and measured cardiac function prior and after 72h of SPARC or vehicle 368 infusion ( Figure 3G ). We found an increased FS in the SPARC treated group, while FS in 369 the vehicle group continued to decline ( Figure 3H ). End diastolic diameter (EDD) was 370 slightly smaller in the SPARC group prior to treatment, compared to the vehicle group.
However, EDD did not change due to the SPARC treatment, while in the vehicle group 372 EDD were slightly decreased after 72h. ESD, on the other hand, was not different between 373 groups or time-points ( Figure 3I ). Moreover, myocyte cross-sectional area and the 374 amount of CD45 positive cells in hearts did not differ between the 2 groups (Table 2 ). Yet, 375
while the amount of fibrosis did not differ, collagen cross-linking was increased in the 376 SPARC-treated group as compared to the vehicle group (Table 2) , confirming the 377 previously demonstrated effect of SPARC on collagen-crosslinking. Nevertheless, despite 378 this higher collagen cross-linking, we found next to increased cardiac contraction, a trend 379 to increasing shortening in isolated cardiomyocytes from these SPARC-treated mice at 380 2Hz pacing cycle length when compared to cells isolated from vehicle-treated mice (Figure  381 3J), with no differences in TTP or RT50 ( Supplementary Figure 2I and J) . In addition, when 382 cardiomyocytes were isolated from these severely sick, untreated mice, incubation of the 383 cells with SPARC for 1h ex vivo resulted in a significant increase in cardiomyocyte 384
shortening, compared to control cells ( Figure 3K ), again without influencing TTP or RT50 385 (Supplementary Figure 2K and L) . 386
387
Finally, when we infused healthy adult mice with SPARC or vehicle for 72h, we also found 388 increased FS compared to baseline measurements and compared to vehicle-mice ( Figure  389 3L). SPARC administration caused decreased end-systolic diameters (ESD), but not end-390 diastolic diameters (EDD), while diameters did not change in hearts of vehicle-mice 391 ( Figure 3M ) Again, SPARC administration did not affect cardiomyocyte hypertrophy, the 392 amount of fibrosis, collagen cross-linking, or the amount of CD45 cells (Table 3) Discussion 394
To our knowledge this study is the first to demonstrate a direct role for a non-structural 395 matrix protein on cardiomyocyte contraction, via interactions of this protein with 396 intracellular effectors. Our previous study on SPARC in myocardial infarction suggested a 397 previously unexplored potential inotropic function for SPARC in the heart. Here, we 398 demonstrated increased cardiac contraction when SPARC was overexpressed, not only in 399 infarcted mice, but also in sham-operated mice [5] yet how SPARC might directly affected 400 cardiomyocyte contraction remained undetermined. Therefore, in this study we aimed to 401 explore the role of SPARC on cardiomyocyte contractility using various ex vivo and in vivo 402 models. We have shown that extracellular SPARC increases cardiomyocyte contraction, 403 during both health and disease, possibly by interacting with the integrin-beta1-ILK 404 complex on the cardiomyocyte membrane. Not only is SPARC able to prevent a decrease 405 in cardiac function, but it is also able to rescue myocytes that are already compromised 406 through viral infection. These data highlight the potential of SPARC as a therapy in VM 407 and potentially in other disease states where cardiac function is equally compromised. 408 409
Earlier research by Barker and colleagues has demonstrated the interaction of SPARC with 410
integrin-beta1 resulting in increased contractile signalling in lung fibroblasts through 411 activation of ILK. Using SPARC null and WT cells they showed that SPARC is required for 412 fibronectin-induced ILK-activation, which resulted in increased contractile signalling 413 through MLC phosphorylation in these pulmonary fibroblasts [18] . In cardiomyocytes, promoting actin-myosin interaction [27] . Our current working hypothesis is that SPARC 416 increases cardiomyocyte contraction through its interaction with the integrin-beta1-ILK 417 complex at the cardiomyocyte membrane. As a consequence, MLC phosphatase activity 418 decreases intracellularly and hence ultimately increases the phosphorylation of MLC2v, 419 causing increased actin-myosin interaction and thus augmented cardiomyocyte 420 contraction (Figure 4 ). In line with Barker et al. [18] we have demonstrated an inotropic 421 function of SPARC but this time in cardiomyocytes. SPARC increases cardiomyocyte 422 fractional shortening possibly through its interaction with integrin-beta1 and increased 423 downstream ILK signalling. Further studies will be required, however, to fully elucidate 424 this mechanism. 425 426 Interestingly, in a study using monoclonal antibodies and peptides, the copper-binding 427 domain of SPARC was identified to be required for the interaction of SPARC with integrin-428 beta1, resulting in increased ILK signalling. In the latter study, stressed lens epithelial cells 429 In the present study we did not investigate a potential protective effect of SPARC on 434 myocyte survival, however we could not find evidence for decreased stress in VM hearts 435 of SPARC overexpressing or SPARC treated mice, as was shown by equal amounts of 436 fibrosis and CD45 positive cells, and the absence of cardiomyocyte hypertrophy in both subsets of hearts. Furthermore, SPARC overexpression did not result in altered levels of 438 phosphorylated Akt, which is known to regulate cardiomyocyte hypertrophy and 439 apoptosis [30, 31] . On the other hand, we did see a slight reduction in leukocyte 
